Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions
Schizophrenia
Interventions
DRUG

Memantine

Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

DRUG

Placebo

Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Trial Locations (1)

92103

University of California, San Diego, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT01555697 - Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia | Biotech Hunter | Biotech Hunter